Recovery after admission with COVID-19 pneumonia – A follow-up study

Brugge, Simone van der Sar–van der; Flikweert, Antine; Mee, Arthur du; Gense, Kim; Talman, Sander; Kant, Merijn R.; Backer, Ingrid de

doi:10.1016/j.resmer.2023.101001

Cited by 1 publication

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 2517 studies were identified, of which 43 met the inclusion (N = 8858 patients) ( Figure 1 ) [ 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 ]. The majority of studies were from China (14 studies [ 51 , 58 , 59 , 60 , 61 , 64 , 65 , …”

Section: Resultsmentioning

confidence: 99%

“…The median age of the patients was 60.3 years (57–63), with 61.5% being males and 37.8% being current/former smokers. Thirty-nine studies [ 47 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 65 , 66 , 67 , 68 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 ] reported outcomes stratified by disease severity; 17 for non-severe disease, 31 for severe disease, and 7 for mixed disease severity ( Table 1 ). The most common comorbidities were hypertension (35.8%), cardiovascular disease, (28%), and obesity (24.9%) ( Supplemental Table S1 ).…”

Section: Resultsmentioning

confidence: 99%

“…A total of 37 studies [ 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 56 , 57 , 60 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 ] reported chest-CT findings at 12 months, while only 3 studies [ 55 , 59 , 61 ] reported findings at 24 months. When comparing CT abnormalities between the 12- and 24-month follow-ups, consolidation (12 months: 3.6% vs. 24 months: 0.9%, p = 0.036) and interlobular septal thickening (12 months: 17.3% vs. 24 months: 7%, p = 0.043) significantly decreased over time.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Short- and Long-Term Chest-CT Findings after Recovery from COVID-19: A Systematic Review and Meta-Analysis

Babar,

Jamil,

Mehta

et al. 2024

Diagnostics

View full text Add to dashboard Cite

While ground-glass opacity, consolidation, and fibrosis in the lungs are some of the hallmarks of acute SAR-CoV-2 infection, it remains unclear whether these pulmonary radiological findings would resolve after acute symptoms have subsided. We conducted a systematic review and meta-analysis to evaluate chest computed tomography (CT) abnormalities stratified by COVID-19 disease severity and multiple timepoints post-infection. PubMed/MEDLINE was searched for relevant articles until 23 May 2023. Studies with COVID-19-recovered patients and follow-up chest CT at least 12 months post-infection were included. CT findings were evaluated at short-term (1–6 months) and long-term (12–24 months) follow-ups and by disease severity (severe and non-severe). A generalized linear mixed-effects model with random effects was used to estimate event rates for CT findings. A total of 2517 studies were identified, of which 43 met the inclusion (N = 8858 patients). Fibrotic-like changes had the highest event rate at short-term (0.44 [0.3–0.59]) and long-term (0.38 [0.23–0.56]) follow-ups. A meta-regression showed that over time the event rates decreased for any abnormality (β = −0.137, p = 0.002), ground-glass opacities (β = −0.169, p < 0.001), increased for honeycombing (β = 0.075, p = 0.03), and did not change for fibrotic-like changes, bronchiectasis, reticulation, and interlobular septal thickening (p > 0.05 for all). The severe subgroup had significantly higher rates of any abnormalities (p < 0.001), bronchiectasis (p = 0.02), fibrotic-like changes (p = 0.03), and reticulation (p < 0.001) at long-term follow-ups when compared to the non-severe subgroup. In conclusion, significant CT abnormalities remained up to 2 years post-COVID-19, especially in patients with severe disease. Long-lasting pulmonary abnormalities post-SARS-CoV-2 infection signal a future public health concern, necessitating extended monitoring, rehabilitation, survivor support, vaccination, and ongoing research for targeted therapies.

show abstract